John Hussman's CPRX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 84,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $2.08 M, representing 0.45% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 64,500 shares. Largest reduction occurred in Q3 2022, reducing 68,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -21,000 | Reduce 20.00% | 84,000 | $24.76 |
| Q4 2025 | -42,000 | Reduce 28.57% | 105,000 | $23.34 |
| Q2 2025 | +63,000 | Add 75.00% | 147,000 | $21.70 |
| Q1 2025 | -21,000 | Reduce 20.00% | 84,000 | $24.25 |
| Q1 2024 | -52,500 | Reduce 33.33% | 105,000 | $15.94 |
| Q3 2023 | +64,500 | Add 69.35% | 157,500 | $11.69 |
| Q1 2023 | +31,000 | Add 50.00% | 93,000 | $16.58 |
| Q3 2022 | -68,000 | Reduce 52.31% | 62,000 | $12.82 |
| Q2 2022 | +62,000 | Add 91.18% | 130,000 | $7.01 |
| Q4 2021 | -56,000 | Reduce 45.16% | 68,000 | $6.76 |
| Q2 2021 | +124,000 | New Buy | 124,000 | $5.75 |
John Hussman's Catalyst Pharmaceuticals Investment FAQs
John Hussman first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q2 2021, acquiring 124,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Catalyst Pharmaceuticals, Inc. (CPRX) for 20 quarters since Q2 2021.
John Hussman's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q2 2021, adding 124,000 shares worth $713,000.
According to the latest 13F filing for Q1 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 84,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $2.08 M.
As of the Q1 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.45% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 157,500 shares, as reported at the end of Q3 2023.